Capricor疗法 CAPR 深 沪
等待开盘 06-30 09:30:00 美东时间
23.80
-2.640
-9.98%
华盛通- 最 高27.05
- 今 开27.01
- 成交量 324.35万股
- 最 低 23.46
- 昨 收 26.44
- 总市值 13.78亿
- 52周最高 40.37
- 市盈率 静 --
- 换手率 5.60%
- 52周最低 4.30
- 委 比 0.49%
- 总股本 5791.19万
- 历史最高 171.50
- 量 比 1.64
- 振 幅 13.58%
- 历史最低 0.88
- 每 手 1
- 风险率 10.99%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Capricor Faces FDA Advisory Review for DMD Therapy
Capricor Therapeutics ( ($CAPR) ) has provided an update. On June 26, 2026, Cap...
06-27 05:53
What's Going On With Capricor Therapeutics Stock On Friday?
Capricor Therapeutics Inc. (NASDAQ:CAPR) stock is trading lower on Friday, down by 13%. The Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) of the U.S. Food and Drug Administration (FDA) is planning to convene an advisory committee meeting to discuss the company’s Biologics License ...
06-27 02:06
戴尔、闪迪跻身周五市值变动显著个股行列
周五美股多只个股出现大幅波动，覆盖从超大盘到小盘不同市值区间，呈现分化行情。 各市值区间异动个股及相关信息如下： 超大盘股（市值2000亿美元及以上）：迈威科...
06-26 22:41
Capricor Therapeutics To Present Data From Its Current HOPE-2 Open-Label Extension Trial Of Deramiocel For Duchenne Muscular Dystrophy At Parent Project Muscular Dystrophy 2026 Annual Conference
Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive five-year data from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the Company’s lead cell therapy candidate for ...
06-26 21:06
Capricor Therapeutics EVP, General Counsel Karen Krasney sells 900 shares for $27,000
Capricor Therapeutics EVP, General Counsel Karen Krasney sells 900 shares for $27,000 Capricor Therapeutics EVP and General Counsel Karen Krasney exercised stock options for 900 shares at USD 3.18 on June 22-24. Krasney sold 900 shares at USD 30 on the same dates. She ended with 30,547 Capricor comm
06-25 08:00
Regenxbio, Replimune among gainers after FDA U-turn on UniQure
Biotechs hit by recent setbacks at the hands of the FDA were making a comeback on Wednesday after the FDA reversed its course on UniQure’s (QURE) gene therapy candidate AMT-130, paving the way for a p...
06-18 02:35
Capricor Therapeutics to Present at Upcoming Investor Conferences
Capricor Therapeutics announced that its senior management will participate in two upcoming investor conferences: the Goldman Sachs 47th Annual Global Healthcare Conference and the Oppenheimer CNS and Neuro-Muscular Summit, both on June 10 in Miami, FL. The company, which focuses on cell and exosome-based therapies for rare diseases, will host fireside chats, investor meetings, and a webcast for the Goldman Sachs event.
06-08 13:25
Capricor publishes investor presentation on deramiocel Duchenne muscular dystrophy program
Capricor publishes investor presentation on deramiocel Duchenne muscular dystrophy program Capricor highlighted FDA review of deramiocel for Duchenne muscular dystrophy with a PDUFA target action date of Aug. 22, 2026. HOPE-3 Phase 3 trial (n=106) met the primary endpoint on PUL v2.0 (p=0.03); key c
05-29 10:16
Capricor names Michael Maurer chief commercial officer
Capricor names Michael Maurer chief commercial officer Capricor Therapeutics appointed Michael Maurer as chief commercial officer, effective immediately, to strengthen launch readiness for Deramiocel in Duchenne muscular dystrophy. Maurer brings about two decades in rare-disease commercialization, p
05-29 09:58
Capricor Therapeutics files Form 3 for Chief Commercial Officer Michael T. Maurer
Capricor Therapeutics files Form 3 for Chief Commercial Officer Michael T. Maurer Capricor Therapeutics filed a Form 3 for Chief Commercial Officer Michael T. Maurer, marking his initial insider ownership disclosure dated May 25, 2026. Disclaimer: This news brief was created by Public Technologies (
05-29 09:52
